Zai Lab (ZLAB) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

ZLAB Stock Forecast


Zai Lab stock forecast is as follows: an average price target of $75.50 (represents a 144.42% upside from ZLAB’s last price of $30.89) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ZLAB Price Target


The average price target for Zai Lab (ZLAB) is $75.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $101.00 to $50.00. This represents a potential 144.42% upside from ZLAB's last price of $30.89.

ZLAB Analyst Ratings


Buy

According to 3 Wall Street analysts, Zai Lab's rating consensus is 'Buy'. The analyst rating breakdown for ZLAB stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Zai Lab Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 27, 2024Jack LinMorgan Stanley$50.00$23.63111.60%61.86%
Apr 21, 2022-Leerink Partners$101.00$42.88135.54%226.97%
Row per page
Go to

The latest Zai Lab stock forecast, released on Sep 27, 2024 by Jack Lin from Morgan Stanley, set a price target of $50.00, which represents a 111.60% increase from the stock price at the time of the forecast ($23.63), and a 61.86% increase from ZLAB last price ($30.89).

Zai Lab Price Target by Period


1M3M12M
# Anlaysts-11
Avg Price Target-$50.00$50.00
Last Closing Price$30.89$30.89$30.89
Upside/Downside-100.00%61.86%61.86%

In the current month, the average price target of Zai Lab stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Zai Lab's last price of $30.89. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 27, 2024Morgan StanleyOverweightOverweightHold
Apr 09, 2024Bank of America SecuritiesBuyBuyHold
Oct 26, 2023Goldman SachsBuyBuyHold
Row per page
Go to

Zai Lab's last stock rating was published by Morgan Stanley on Sep 27, 2024. The company gave ZLAB a "Overweight" rating, the same as its previous rate.

Zai Lab Financial Forecast


Zai Lab Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
Revenue---------$69.23M$68.86M$62.80M$62.60M$57.54M$48.18M$46.72M$44.17M$43.10M$36.94M$20.10M$15.09M$14.65M$10.99M$8.22M$4.65M
Avg Forecast$137.50M$130.30M$123.00M$117.30M$107.20M$102.24M$93.16M$75.24M$72.14M$66.41M$70.48M$65.12M$62.79M$53.75M$47.13M$44.58M$47.89M$43.77M$27.41M$17.66M$25.45M$15.83M$-1.64M$36.00K$10.00M
High Forecast$137.50M$130.30M$123.00M$117.30M$107.20M$106.68M$93.16M$75.24M$76.07M$69.27M$70.48M$65.12M$62.79M$53.75M$47.13M$44.58M$47.89M$43.77M$27.41M$17.66M$25.45M$15.83M$-1.64M$36.00K$10.00M
Low Forecast$137.50M$130.30M$123.00M$117.30M$107.20M$99.52M$93.16M$75.24M$67.70M$63.55M$70.48M$65.12M$62.79M$53.75M$47.13M$44.58M$47.89M$43.77M$27.41M$17.66M$25.45M$15.83M$-1.64M$36.00K$10.00M
# Analysts3333454454443333444444443
Surprise %---------1.04%0.98%0.96%1.00%1.07%1.02%1.05%0.92%0.98%1.35%1.14%0.59%0.93%-6.71%228.28%0.46%

Zai Lab's average Quarter revenue forecast for Dec 23 based on 5 analysts is $72.14M, with a low forecast of $67.70M, and a high forecast of $76.07M. ZLAB's average Quarter revenue forecast represents a 4.21% increase compared to the company's last Quarter revenue of $69.23M (Sep 23).

Zai Lab EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts3333454454443333444444443
EBITDA---------$-83.57M$-89.50M$-78.43M$-136.00M$-126.36M$-96.86M$-77.75M$-209.95M$-94.78M$-161.80M$-231.46M$-75.14M$-62.55M$-79.54M$-46.86M$-45.14M
Avg Forecast$-137.50M$-130.30M$-123.00M$-117.30M$-107.20M$-102.24M$-93.16M$-75.24M$-72.14M$-66.41M$-70.48M$-65.12M$-16.95M$-53.75M$-47.13M$-44.58M$-47.89M$-43.77M$-27.41M$-178.77M$-25.45M$-15.83M$1.64M$-36.00K$-18.13M
High Forecast$-137.50M$-130.30M$-123.00M$-117.30M$-107.20M$-99.52M$-93.16M$-75.24M$-67.70M$-63.55M$-70.48M$-65.12M$-13.56M$-53.75M$-47.13M$-44.58M$-47.89M$-43.77M$-27.41M$-143.01M$-25.45M$-15.83M$1.64M$-36.00K$-14.50M
Low Forecast$-137.50M$-130.30M$-123.00M$-117.30M$-107.20M$-106.68M$-93.16M$-75.24M$-76.07M$-69.27M$-70.48M$-65.12M$-20.34M$-53.75M$-47.13M$-44.58M$-47.89M$-43.77M$-27.41M$-214.52M$-25.45M$-15.83M$1.64M$-36.00K$-21.75M
Surprise %---------1.26%1.27%1.20%8.02%2.35%2.06%1.74%4.38%2.17%5.90%1.29%2.95%3.95%-48.56%1301.64%2.49%

undefined analysts predict ZLAB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Zai Lab's previous annual EBITDA (undefined) of $NaN.

Zai Lab Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts3333454454443333444444443
Net Income---------$-69.15M$-120.89M$-28.77M$-26.25M$-158.96M$-136.07M$-84.80M$-203.94M$-109.28M$-155.67M$-238.92M$-57.39M$-50.96M$-77.02M$-49.52M$-40.56M
Avg Forecast$-27.33M$-50.26M$-54.16M$-56.60M$-79.36M$-76.40M$-69.13M$-90.26M$-83.52M$-101.90M$-77.14M$-92.53M$-17.43M$-121.87M$-104.98M$-122.99M$-130.17M$-114.98M$-103.61M$-179.89M$-165.42M$-165.42M$-58.10M$-61.42M$-18.65M
High Forecast$-27.33M$-50.26M$-54.16M$-56.60M$-79.36M$-69.27M$-69.13M$-90.26M$-74.88M$-101.90M$-77.14M$-92.53M$-13.95M$-121.87M$-104.98M$-122.99M$-130.17M$-114.98M$-103.61M$-143.91M$-165.42M$-165.42M$-58.10M$-61.42M$-14.92M
Low Forecast$-27.33M$-50.26M$-54.16M$-56.60M$-79.36M$-85.57M$-69.13M$-90.26M$-93.12M$-101.90M$-77.14M$-92.53M$-20.92M$-121.87M$-104.98M$-122.99M$-130.17M$-114.98M$-103.61M$-215.86M$-165.42M$-165.42M$-58.10M$-61.42M$-22.37M
Surprise %---------0.68%1.57%0.31%1.51%1.30%1.30%0.69%1.57%0.95%1.50%1.33%0.35%0.31%1.33%0.81%2.18%

Zai Lab's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ZLAB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Zai Lab SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts3333454454443333444444443
SG&A---------$68.55M$67.92M$62.51M$72.02M$66.56M$63.40M$56.99M$69.58M$59.00M$54.41M$35.84M$40.97M$27.87M$23.76M$18.71M$23.02M
Avg Forecast$315.08M$298.58M$281.85M$268.79M$245.65M$234.28M$213.48M$8.42M$165.31M$152.17M$161.50M$9.00M$8.65M$123.16M$107.98M$9.63M$109.75M$100.31M$62.80M$40.46M$58.32M$36.28M$-3.75M$82.49K$9.25M
High Forecast$315.08M$298.58M$281.85M$268.79M$245.65M$244.45M$213.48M$10.10M$174.32M$158.73M$161.50M$10.80M$10.37M$123.16M$107.98M$11.55M$109.75M$100.31M$62.80M$40.46M$58.32M$36.28M$-3.75M$82.49K$11.10M
Low Forecast$315.08M$298.58M$281.85M$268.79M$245.65M$228.05M$213.48M$6.73M$155.14M$145.62M$161.50M$7.20M$6.92M$123.16M$107.98M$7.70M$109.75M$100.31M$62.80M$40.46M$58.32M$36.28M$-3.75M$82.49K$7.40M
Surprise %---------0.45%0.42%6.95%8.33%0.54%0.59%5.92%0.63%0.59%0.87%0.89%0.70%0.77%-6.33%226.86%2.49%

Zai Lab's average Quarter SG&A projection for Dec 23 is $165.31M, based on 5 Wall Street analysts, with a range of $155.14M to $174.32M. The forecast indicates a 141.14% rise compared to ZLAB last annual SG&A of $68.55M (Sep 23).

Zai Lab EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts3333454454443333444444443
EPS---------$-0.71$-0.00$-0.30$-0.27$-1.66$-1.42$-0.89$-2.15$-1.15$-1.67$-2.70$-0.65$-0.68$-1.03$-0.68$-0.56
Avg Forecast$-0.28$-0.52$-0.56$-0.58$-0.81$-0.78$-0.71$-0.92$-0.86$-1.04$-0.79$-0.95$-1.11$-1.25$-1.08$-1.26$-1.33$-1.18$-1.06$-1.58$-1.70$-1.70$-0.60$-0.63$-0.94
High Forecast$-0.28$-0.52$-0.56$-0.58$-0.81$-0.71$-0.71$-0.92$-0.77$-1.04$-0.79$-0.95$-1.11$-1.25$-1.08$-1.26$-1.33$-1.18$-1.06$-1.58$-1.70$-1.70$-0.60$-0.63$-0.94
Low Forecast$-0.28$-0.52$-0.56$-0.58$-0.81$-0.88$-0.71$-0.92$-0.95$-1.04$-0.79$-0.95$-1.11$-1.25$-1.08$-1.26$-1.33$-1.18$-1.06$-1.58$-1.70$-1.70$-0.60$-0.63$-0.94
Surprise %---------0.68%0.00%0.32%0.24%1.33%1.32%0.71%1.61%0.98%1.57%1.71%0.38%0.40%1.73%1.08%0.60%

According to undefined Wall Street analysts, Zai Lab's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ZLAB previous annual EPS of $NaN (undefined).

Zai Lab Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
APLSApellis Pharmaceuticals$28.56$76.13166.56%Buy
ZLABZai Lab$30.89$75.50144.42%Buy
ERASErasca$2.87$7.00143.90%Buy
CCCCC4 Therapeutics$6.45$13.50109.30%Buy
CGEMCullinan Oncology$15.92$31.5097.86%Buy
LEGNLegend Biotech$43.61$82.6289.45%Buy
ASNDAscendis Pharma$125.77$190.2151.24%Buy
AKROAkero Therapeutics$32.05$46.0043.53%Buy
ROIVRoivant Sciences$11.53$16.2140.59%Buy
BPMCBlueprint Medicines$91.88$109.7119.41%Buy
PTCTPTC Therapeutics$40.39$46.5015.13%Hold
KRYSKrystal Biotech$170.85$191.0011.79%Buy
MDGLMadrigal Pharmaceuticals$331.32$315.75-4.70%Buy
ALNYAlnylam Pharmaceuticals$269.95$254.21-5.83%Buy
RXDXPrometheus Biosciences$199.92$138.57-30.69%Buy

ZLAB Forecast FAQ


Yes, according to 3 Wall Street analysts, Zai Lab (ZLAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ZLAB's total ratings.

Zai Lab (ZLAB) average price target is $75.5 with a range of $50 to $101, implying a 144.42% from its last price of $30.89. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for ZLAB stock, the company can go up by 144.42% (from the last price of $30.89 to the average price target of $75.5), up by 226.97% based on the highest stock price target, and up by 61.86% based on the lowest stock price target.

ZLAB's average twelve months analyst stock price target of $75.5 supports the claim that Zai Lab can reach $50 in the near future.

Zai Lab's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $377.85M (high $382.28M, low $375.12M), average EBITDA is $-378M (high $-375M, low $-382M), average net income is $-315M (high $-308M, low $-324M), average SG&A $701.82M (high $713.67M, low $693.9M), and average EPS is $-3.229 (high $-3.156, low $-3.323). ZLAB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $508.1M (high $508.1M, low $508.1M), average EBITDA is $-508M (high $-508M, low $-508M), average net income is $-188M (high $-188M, low $-188M), average SG&A $1.16B (high $1.16B, low $1.16B), and average EPS is $-1.93 (high $-1.93, low $-1.93).

Based on Zai Lab's last annual report (Dec 2023), the company's revenue was $266.72M, which missed the average analysts forecast of $274.15M by -2.71%. Apple's EBITDA was $-367M, beating the average prediction of $-274M by 33.71%. The company's net income was $-335M, missing the average estimation of $-355M by -5.76%. Apple's SG&A was $281.61M, missing the average forecast of $487.99M by -42.29%. Lastly, the company's EPS was $-34.63, beating the average prediction of $-3.638 by 851.80%. In terms of the last quarterly report (Sep 2023), Zai Lab's revenue was $69.23M, beating the average analysts' forecast of $66.41M by 4.24%. The company's EBITDA was $-83.57M, beating the average prediction of $-66.41M by 25.84%. Zai Lab's net income was $-69.152M, missing the average estimation of $-102M by -32.14%. The company's SG&A was $68.55M, missing the average forecast of $152.17M by -54.95%. Lastly, the company's EPS was $-0.71, missing the average prediction of $-1.044 by -32.00%